TriKE therapeutic (GT Biopharma)

N/A

Report date: 2025/01/26 17:47:59

Base Information

Drug NameTriKE therapeutic (GT Biopharma)

Drug Alias Nameanti-SARS-CoV-2 program (GT Biopharma)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionInterleukin-15 receptors agonistsLow affinity immunoglobulin gamma Fc region receptor III agonistsAngiotensin-converting enzyme 2 modulators

TargetsInterleukin-15 receptorsLow affinity immunoglobulin gamma Fc region receptor IIIAngiotensin-converting enzyme 2

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGt Biopharma Inc

China Registration ClassN/A

Develop Information

Active CompaniesGt Biopharma Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A